In 47 human breast cancer and immortalized cell lines representing the known molecular subgroups of breast cancer, palbociclib was tested and showed a differential effect on those cell lines with an emphasize on hormone-receptor-positive and HER2-amplified ones [62]. This evidence concerns the gene ERBB2 and breast carcinoma.